Summary
ICY Chart
Incyte Corporation (INCY) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So welcome to this fireside chat with Incyte.
Incyte: Maintaining Buy As 2 Untapped Opportunities Emerge In Oncology Portfolio
Incyte Corporation remains a Buy supported by strong Q3 2025 earnings, robust revenue growth, and raised full-year 2025 guidance. INCY advances its pipeline with promising data for povorcitinib in HS, PN, vitiligo, and asthma, with regulatory filings expected by early 2026. Oncology portfolio expansion is driven by INCA33890 for MSS colorectal cancer and INCB161734 for KRASG12D-mutated PDAC, both showing encouraging response rates.
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Incyte Corporation (ICY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Incyte Corporation ever had a stock split?
Incyte Corporation Profile
| Biotechnology Industry | Healthcare Sector | Herve Hoppenot CEO | XHAN Exchange | US45337C1027 ISIN |
| US Country | 2,617 Employees | - Last Dividend | 1 Sep 2000 Last Split | 4 Nov 1993 IPO Date |
Overview
Incyte Corporation is a prominent biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics. With a broad interest in hematology/oncology and inflammation and autoimmunity sectors, Incyte operates both within the United States and on an international scale. Originally founded in 1991 and known as Incyte Genomics Inc., the company underwent a name change to Incyte Corporation in March 2003. It has established a formidable presence in the pharmaceutical industry, not only through the inception of proprietary drugs but also via strategic collaborations and in-license agreements with other leading biotech entities such as Novartis, Lilly, Agenus, Merus, MacroGenics, Syndax, and China Medical System Holdings Limited. Headquartered in Wilmington, Delaware, Incyte holds a pivotal role in pushing forward the boundaries of medical research and patient care in critical disease areas.
Products and Services
- JAKAFI (ruxolitinib)
A cornerstone in Incyte's portfolio, JAKAFI is approved for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. Its mechanism targets aberrant signaling pathways to curb disease progression.
- MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)
Designed for patients with relapsed or refractory diffuse large B-cell lymphoma; a testament to Incyte's commitment to addressing unmet needs in oncology.
- PEMAZYRE (pemigatinib)
Acts as a fibroblast growth factor receptor kinase inhibitor, targeting oncogenic drivers in various liquid and solid tumor types, showcasing Incyte's innovative approach in targeted cancer therapy.
- ICLUSIG (ponatinib)
Approved for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, providing a targeted therapeutic option for these hematologic cancers.
- ZYNYZ (retifanlimab-dlwr)
This drug is deployed in the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma, underscoring the company's dedication to rare oncology indications.
- OPZELURA cream
Marketed for the treatment of atopic dermatitis, this offering diversifies Incyte's portfolio into the dermatological field, addressing a common yet challenging chronic skin condition.
In addition to these marketed products, Incyte's clinical stage pipeline showcases a robust commitment to innovation through a variety of compounds under development, including retifanlimab for additional cancers, axatilimab for chronic GVHD, and a range of molecules designed to tackle solid tumors. The depth and breadth of Incyte's clinical research reflect its continuous pursuit of therapeutic advances to improve patient outcomes in areas of significant unmet medical need.
Contact Information
